Ryoncil (remestemcel-L-rknd) - MEDICAID - SOUTH CAROLINA

This policy covers Ryoncil (remestemcel‑L‑rknd), an allogeneic bone marrow‑derived mesenchymal stromal cell therapy, for treatment of steroid‑refractory acute graft‑versus‑host disease (SR‑aGVHD). Coverage is limited to pediatric patients 2 months to 17 years with Grade B–D aGVHD after allogeneic HCT who meet the steroid‑refractory timing (disease progression by day 5 or no improvement by day 7 on ≥2 mg/kg/day methylprednisolone or equivalent), and requires medical director review/prior authorization, specified IV dosing (twice weekly for 4 weeks, ≥3 days apart), adequate renal function (CrCl >30 mL/min/1.73 m2), and exclusion of other causes of diarrhea for GI‑predominant disease.

"Allogeneic (donor) hematopoietic cell transplantation (HCT) as a conventional and potentially curative treatment for childhood blood cancers"

Sign up to see full coverage criteria, indications, and limitations.